Videos

A brief review of the identification and management of capillary leak syndrome in patients being treated for blastic plasmacytoid dendritic cell neoplasm.

Eric Jonasch, MD, discusses the 3-year follow-up of the LITESPARK-001 trial of belzutifan in patients with clear cell renal cell carcinoma.

Expert perspectives on the first-line use of tagraxofusp, a CD123-directed therapy, in patients with blastic plasmacytoid dendritic cell neoplasm.

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Centering discussion on polycythemia vera, Rami S. Komrokji, MD, and Pankit Vachhani, MD, share an in-depth review of cornerstone therapies in this setting.

Expert hematologist-oncologists share insight on the pathways driving myeloproliferative neoplasms and biomarkers that may be targeted with novel therapy.

Jonathan E. Rosenberg, MD, discusses what has been previously shown with enfortumab vedotin for patients with locally advanced metastatic urothelial cancer.

Lajos Pusztai, MD, DPhil, discusses the promise of neoadjuvant immunotherapy trials including the KEYNOTE-522 trial evaluating pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.

David S. Hong, MD, discusses larotrectinib and its mechanism of action.

Adam Weiner, MD, discusses next steps for molecular testing in prostate cancer.

Joseph Mikhael, MD, discusses the ongoing impact of daratumumab in the treatment landscape of patients with multiple myeloma.

Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.

Melina E. Marmarelis, MD, reports the rationale and key findings from the Chrysalis-2 trial of patients with EGFR-mutated advanced non–small cell lung cancer.

Eytan M. Stein, MD, defines Menin inhibition and its role in the leukemia space.

Shannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.

Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.

Dr Nizar Tannir describes data presented at ASCO 2022 from EVEREST investigating everolimus vs placebo for patients with high-risk disease.

Experts discuss the use of pembrolizumab as an adjuvant therapy in advanced clear cell RCC.

Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.

Deena Mary Atieh Graham, MD, discusses the treatment options for a breast cancer diagnosis and explains how patients are affected after treatment.

Dr Bardia talks about the role of biomarker testing and provides an overview of factors which may contribute to a clinician’s choice of treatment strategy for patients with ER+/HER- mBC.

Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.

Rupesh R. Kotecha, MD, discusses a newer radiation modality known as pulse reduced dose rate radiation therapy.

Cristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.

Centering discussion on the first patient case of BPDCN, expert panelists highlight various assessment tools that may help overcome barriers to an early diagnosis.

Shared insight on methods to identify blastic plasmacytoid dendritic cell neoplasm followed by updated classifications from the World Health Organization.

Broad perspective on diagnosis of the myeloproliferative neoplasms via optimal workup and molecular testing.

In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.

A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.